BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35902333)

  • 1. Nutritional status in patients with hepatocellular carcinoma: Potential relevance for clinical outcome.
    van Dijk AM; Coppens BJP; van Beers MA; Bruins Slot AS; Verstraete CJR; de Bruijne J; Vleggaar FP; van Erpecum KJ
    Eur J Intern Med; 2022 Oct; 104():80-88. PubMed ID: 35902333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
    Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
    J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization.
    Adhoute X; Pénaranda G; Raoul JL; Bollon E; Pol B; Letreut YP; Perrier H; Bayle O; Monnet O; Beaurain P; Muller C; Hardwigsen J; Lefolgoc G; Castellani P; Bronowicki JP; Bourlière M
    Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):706-715. PubMed ID: 28195873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
    Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
    Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.
    Ni JY; Sun HL; Chen YT; Luo JH; Chen D; Jiang XY; Xu LF
    World J Gastroenterol; 2014 Dec; 20(46):17483-90. PubMed ID: 25516662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
    Piñero F; Marciano S; Fernández N; Silva J; Anders M; Zerega A; Ridruejo E; Romero G; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Reggiardo V; Colombato L; Gadano A; Silva M
    World J Gastroenterol; 2019 Jul; 25(27):3607-3618. PubMed ID: 31367160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial chemoembolization in unresectable hepatocellular carcinoma--assessing the factors affecting the survival: An audit from a tertiary care center in northern India.
    Agarwal A; Yadav AK; Kumar A; Gupta S; Panwala HK; Redhu N; Hariprasad S; Ranjan P; Arora A; Gupta A
    Indian J Gastroenterol; 2015 Mar; 34(2):117-26. PubMed ID: 25937484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study.
    Xue T; Le F; Chen R; Xie X; Zhang L; Ge N; Chen Y; Wang Y; Zhang B; Ye S; Ren Z
    Med Oncol; 2015 Mar; 32(3):64. PubMed ID: 25682389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma.
    Kloeckner R; Pitton MB; Dueber C; Schmidtmann I; Galle PR; Koch S; Wörns MA; Weinmann A
    J Vasc Interv Radiol; 2017 Jan; 28(1):94-102. PubMed ID: 27562621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C.
    Li L; Gou CY; Li JY; Achakzai R; Li XH
    Hepatobiliary Pancreat Dis Int; 2016 Apr; 15(2):152-7. PubMed ID: 27020631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience.
    Varghese J; Kedarisetty C; Venkataraman J; Srinivasan V; Deepashree T; Uthappa M; Ilankumaran K; Govil S; Reddy M; Rela M
    Ann Hepatol; 2017; 16(2):247-254. PubMed ID: 28233748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
    Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
    J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
    J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma.
    Hickey R; Mouli S; Kulik L; Desai K; Thornburg B; Ganger D; Baker T; Abecassis M; Ralph Kallini J; Gabr A; Gates VL; Benson Iii AB; Lewandowski RJ; Salem R
    J Vasc Interv Radiol; 2016 Jun; 27(6):795-802. PubMed ID: 27038686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
    Biolato M; Gallusi G; Iavarone M; Cabibbo G; Racco S; De Santis A; Corte CD; Maida M; Attili AF; Sangiovanni A; Cammà C; La Torre G; Gasbarrini A; Grieco A
    Ann Hepatol; 2018; 17(1):110-118. PubMed ID: 29311396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Combined Radiofrequency Ablation with Transarterial Chemoembolization in Patients with Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma Ineligible for Curative Treatment.
    Kim AR; Park E; Kwon SY; Park SJ; Kim YJ; Yoo BC; Choe WH; Kim JH; Hwang JH; Park SW; Kim YJ; Park HS; Yu MH; Jeon HJ
    Korean J Gastroenterol; 2019 Mar; 73(3):167-176. PubMed ID: 31013560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of hepatic resection in patients with intermediate-stage hepatocellular carcinoma: A multicenter study from Japan.
    Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Itobayashi E; Nouso K; Kariyama K; Ishikawa T; Hirooka M; Hiasa Y
    Cancer Sci; 2017 Jul; 108(7):1414-1420. PubMed ID: 28406546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
    Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
    J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.
    Gomaa AI; Al-Khatib A; Abdel-Razek W; Hashim MS; Waked I
    World J Gastroenterol; 2015 May; 21(18):5654-62. PubMed ID: 25987792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.